Search
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedA thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...
Valdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGluconic Acid
go.drugbank.com/drugs/DB13180ApprovedInvestigationalCommonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.
Synonyms: D-Gluconic AcidMixtures: ELETTROLITICA DI REINTEGRAZIONE PH 7,4 CON SODIO GLUCONATO FKI, ELETTROLITICA DI REINTEGRAZIONE PH 7,4 CON SODIO GLUCONATO FKIPegloticase
go.drugbank.com/drugs/DB09208ApprovedInvestigationalPegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. … Therefore therapeutic drug levels can be maintained with infrequent and relatively low pegloticase doses.[A249980] The PEG group also gives pegloticase a lower potential to induce an immune response.
Acepromazine
go.drugbank.com/drugs/DB01614InvestigationalVet approvedAcepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.
Categories: Dopamine D2 Receptor AntagonistsDoxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDrospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use. … [L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.
Mixtures: ACTIVA DE +TABLETAS RECUBIERTASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLufotrelvir
go.drugbank.com/drugs/DB16514InvestigationalOnce administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects[L31718]. … Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167).
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.
Mixtures: JARDIANZ DUO, JARDIANCE DUOCategories: P-glycoprotein substratesBendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawnBendazac is an oxyacetic acid [A39863, A39869]. … Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although